Indian pharmaceutical major Cipla has taken a significant step to strengthen respiratory healthcare by launching India’s first dedicated lung diagnostics and wellness centre, the Breathefree Lung Wellness Center, in Lajpat Nagar, Delhi. The facility is designed as a one‑stop destination for advanced lung testing and comprehensive respiratory care first‑of‑its‑kind initiative in the country.
The centre offers over 60 specialised diagnostic tests, including advanced pulmonary function assessments such as spirometry, oscillometry, DLCO, body plethysmography, FeNO testing, cardiopulmonary exercise testing (CPET), as well as radiology services like X‑ray and CT scans, sleep studies and detailed microbiological and biochemical analyses. These services help in the detection and management of a wide range of respiratory conditions from asthma, COPD, and lung fibrosis to bronchiectasis and other complex lung diseases.
Beyond diagnostics, the centre also offers pulmonary rehabilitation, nutritional counselling, smoking‑cessation support, personalised breathing therapy and long‑term lung wellness programmes, addressing both disease detection and patient care.
Respiratory diseases are a growing health concern in India, with millions affected by chronic lung conditions that often go undiagnosed or misdiagnosed due to limited access to advanced pulmonary testing. The new centre aims to bridge this gap by making standardised, high‑quality lung diagnostics more accessible and affordable for patients and doctors alike.
According to Cipla, the Breathefree initiative builds on the company’s longstanding commitment to respiratory care, strengthening the continuum of care from early detection to personalised treatment and long‑term support.
